Bio Green Med Solution, Inc.
BGMS
NASDAQ Global Market1.09
USD
+0.02
- -
CIK
0001130166
ISIN
US23254L8761
CUSIP
23254L876
Return %
Stock
S&P500
1Y
-81.89
26.53
3Y
-81.89
76.60
5Y
-81.89
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Sing Ee Wong
- Full Time Employees
- 12
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- Level 10 Kuala Lumpur United States of America 592000
- IPO Date
- Sep 12, 2025
- CIK
- 0001130166
- Website
- bgmsglobal.com
- Similar Companies
- Business
- Bio Green Med Solution, Inc. is a diversified company operating primarily in the biopharmaceutical and fire protection industries. Founded in 1996 and headquartered in Berkeley Heights, New Jersey, the company focuses on developing innovative cancer medicines based on cell cycle, transcriptional regulation, and DNA damage response biology. Its biopharmaceutical product pipeline includes novel drug candidates such as CYC065, seliciclib, sapacitabine, and plogosertib, targeting hematology and oncology indications. Alongside its pharmaceutical activities, Bio Green Med Solution has expanded into the fire protection sector through the strategic acquisition and integration of Fitters Sdn. Bhd., a Malaysia-based group specializing in fire protection products and services, following its acquisition completion in September 2025. This acquisition marks a significant operational shift, diversifying the company’s portfolio beyond pharmaceuticals into fire safety materials, equipment trading, and installation services across multiple geographies including the United States, United Kingdom, and Malaysia. The company also completed a $3 million funding round in June 2025 involving the issuance of Series F Preferred Stock and Warrants, supporting its dual-sector growth strategy. Bio Green Med Solution operates with a vision to create sustainable value and advance human development by combining pharmaceutical innovation with fire protection solutions, reflecting its recent rebranding from Cyclacel Pharmaceuticals to Bio Green Med Solution, Inc. in 2022 to better represent its broader business scope. The company's operations thus span clinical-stage cancer drug development, fire safety product distribution, and installation, targeting healthcare providers, government agencies, and commercial clients globally.
BIO GREEN MED SOLUTION REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
BIO GREEN MED SOLUTION REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Cyclacel Pharmaceuticals (NASDAQ:BGMS) vs. Syros Pharmaceuticals (NASDAQ:SYRS) Head to Head Analysis
Analyzing Cyclacel Pharmaceuticals (NASDAQ:BGMS) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT)
Comparing Achaogen (OTCMKTS:AKAOQ) and Cyclacel Pharmaceuticals (NASDAQ:BGMS)
Bio Green Med Solution Reports Third Quarter Financial Results and Provides Business Update